The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of durvalumab, doxorubicin, and ifosfamide in recurrent and/or metastatic pulmonary sarcomatoid carcinoma (KCSG LU-19-24).
 
Bhumsuk Keam
Honoraria - AstraZeneca; Bayer; LG Chem; MSD Oncology; Yuhan
Consulting or Advisory Role - Handok; ImmuneOncia; TiumBio; Trial Informatics; Yuhan
Research Funding - AstraZeneca; MSD Oncology; Ono Pharmaceutical
 
Jeonghwan Youk
Honoraria - Astellas Pharma; AstraZeneca; Boryung Pharmaceuticals; Celltrion; Merck; Novartis; Novartis; Yuhan
Consulting or Advisory Role - Boryung Pharmaceuticals; Daiichi Sankyo/Astra Zeneca
Research Funding - Alkermes; Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca (Inst); Eisai; Genentech; Gilead Sciences; Immunomedics; Incyte; Iovance Biotherapeutics; Lilly; Merck; Pfizer; Roche; Scholar Rock; Selexine
Travel, Accommodations, Expenses - Roche/Genentech
 
Tae Min Kim
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Chong Kun Dang Pharmaceutical; Daiichi Sankyo/Astra Zeneca; inno.N; Janssen Oncology; Merck KGaA; Novartis; Regeneron; Roche; Samsung Bioepis; Takeda
Speakers' Bureau - Amgen; AstraZeneca/MedImmune; Janssen Research & Development; Takeda
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boryung (Inst); Bristol Myers Squibb Foundation (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Dizal Pharma (Inst); Enliven Therapeutics (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); Hanmi (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); Yuhan (Inst)
 
Gyeong-Won Lee
No Relationships to Disclose
 
Dong-Wan Kim
Research Funding - Alpha Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); BridgeBio Pharma (Inst); Chong Kun Dang Pharmaceutical (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); IMBdx (Inst); inno.N (Inst); Janssen (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst); TP Therapeutics (Inst); Xcovery (Inst); Yuhan (Inst); Zymeworks (Inst)
 
Miso Kim
Honoraria - Astellas Pharma; Bristol Myers Squibb; Janssen; Merck; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Boryung; Bristol-Myers Squibb; Janssen; Merck; MSD; Ono Pharmaceutical; Pfizer; Takeda; Yuhan
Travel, Accommodations, Expenses - Regeneron